转移性肾细胞癌一线免疫治疗:纳入三联疗法的更新网状Meta分析
该网状Meta分析纳入7项随机对照试验,比较中危和低危转移性肾细胞癌患者一线免疫检查点抑制剂联合方案的疗效。结果显示帕博利珠单抗+仑伐替尼在无进展生存期和客观缓解率方面排名最高,三联疗法未显示更优疗效,且因毒性和总生存数据不成熟,仅应考虑用于特定患者。
要点
- 帕博利珠单抗+仑伐替尼在改善无进展生存期和客观缓解率方面排名最高。
- 在纳武利尤单抗+卡博替尼基础上加用伊匹木单抗未改善无进展生存期(HR 1.02,95%CI 0.72-1.43)。
- 考虑毒性和总生存数据不成熟,三联疗法仅应考虑用于特定患者。
核心结论
- 帕博利珠单抗+仑伐替尼作为中危或低危IMDC风险转移性肾细胞癌患者的一线治疗具有稳健疗效。
- 三联疗法未产生更优疗效。
- 考虑毒性和缺乏成熟的总生存数据,三联疗法仅应考虑用于特定患者。
研究设计与样本
- 检索三个数据库(截至2022年12月)中分析转移性肾细胞癌患者一线免疫检查点抑制剂联合治疗肿瘤学结局的随机对照试验。
- 共纳入7项随机对照试验进行Meta分析和网状Meta分析。
- 比较中危和低危转移性肾细胞癌患者的无进展生存期和客观缓解率,并评估治疗相关不良事件。
主要发现
- 治疗排名分析显示,帕博利珠单抗+仑伐替尼(99%)具有最高的改善无进展生存期可能性,其次为纳武利尤单抗+卡博替尼(79%)和纳武利尤单抗+伊匹木单抗+卡博替尼(77%)。
- 与纳武利尤单抗+卡博替尼相比,在纳武利尤单抗+卡博替尼基础上加用伊匹木单抗未改善无进展生存期(HR 1.02,95%CI 0.72-1.43)。
- 关于客观缓解率,治疗排名分析显示帕博利珠单抗+仑伐替尼具有最高的提供更优客观缓解率的可能性(99.7%)。
- 帕博利珠单抗+仑伐替尼改善无进展生存期和客观缓解率的可能性在两个IMDC风险组中均成立。
临床怎么用
- 作者认为,考虑毒性和缺乏成熟的总生存数据,三联疗法仅应考虑用于特定患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the differential efficacy of first-line immune checkpoint inhibitor (ICI)-based combined therapies among patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. PATIENTS AND METHODS: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first-line ICI-based combined therapies. We performed network meta-analysis (NMA) to compare the outcomes, including progression-free survival (PFS) and objective response rates (ORRs), in patients with intermediate- and poor-risk mRCC; we also assessed treatment-related adverse events. RESULTS: Overall, seven RCTs were included in the meta-analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72-1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups. CONCLUSIONS: Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first-line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients.
引用
- Yanagisawa T, Kawada T, Bekku K, et al. First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy. BJU Int. 2024. PMID: 38659099. doi:10.1111/bju.16336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。